Carbidopa drug data and news

---

Treating Parkinson's Disease  Mar 3, 2006
Treatments are aimed at improving symptoms and quality of life. One common therapy is a combination of the drugs levodopa and carbidopa. ... - WSOCtv.com,

Valeant Pharmaceuticals Receives FDA Approval of Less-Restrictive ...  Feb 22, 2006
...tolcapone), the company's COMT (catechol-O-methyltransferase) inhibitor product for Parkinson's disease patients undergoing treatment with levodopa/carbidopa. ... - Genetic Engineering News,

Valeant Pharmaceuticals Receives FDA Approval of Less-Restrictive ...  Feb 22, 2006
...tolcapone), thecompany's COMT (catechol-O-methyltransferase) inhibitor product forParkinson's disease patients undergoing treatment withlevodopa/carbidopa. ... - Finanzen.net,

Orion Oyj: Orion group 2005 financial statements  Feb 9, 2006
...together with Novartis, launched a follow-up development, Stalevo®, which combines the standard treatment levodopa with entacapone and carbidopa, the two ... - Kauppalehti (press release),

Mylan Reports Third Quarter Adjusted Diluted EPS of $0.25  Feb 2, 2006
Continued competition on certain products, primarily omeprazole, carbidopa/levodopa and Amnesteem(TM), was responsible for the overall unfavorable pricing and ... - MSN Money

Orion Oyj: Orion group 2005 financial statements  09 Feb 2006
...together with Novartis, launched a follow-up development, Stalevo®, which combines the standard treatment levodopa with entacapone and carbidopa, the two ... - Kauppalehti (press release),

Mylan Reports Third Quarter Adjusted Diluted EPS of $0.25  Feb 2, 2006
Continued competition on certain products, primarily omeprazole, carbidopa/levodopa and Amnesteem(TM), was responsible for the overall unfavorable pricing and ... - MSN Money

International Approvals: Tasmar, Amplimexon, IV Remodulin  Jan 17, 2006
...and reversible catechol-O-methyltransferase (COMT) inhibitor is indicated for use in combination with levodopa/benserazide or levodopa/carbidopa in patients ... - Medscape (subscription)

One day at a time with Parkinson's  Jan 10, 2006
...developing a cure. Today, the most widely prescribed treatment is a combination of two drugs, Levodopa and Carbidopa. They are described ... - Globe and Mail,

IMPAX Settles Patent Suit and Signs Marketing and Promotion ...  Jan 19, 2006
...target market for Carbatrol of approximately 8,300 neurologists in the US overlaps with the Company's target market for Vadova(TM) (carbidopa and levodopa). ... - Genetic Engineering News,

Solvay Pharmaceuticals completes market authorization in 28 ...  Nov 27, 2005
...and unique treatment based on continuous dopaminergic stimulation by means of a formulation of the well-known substances, levodopa and carbidopa, dispersed as ... - LCI,

Cita NeuroPharmaceuticals Inc. Accepts Offer by UK-Based Vernalis ...  Nov 18, 2005
CNP1512 is an innovative, patented effervescent formulation combining levodopa methyl-ester, a more soluble form of levodopa, and carbidopa which is expected ... - Yahoo! News (press release)

DR GARETH: CASEBOOK AZ: R IS FOR RESTLESS LEGS  Nov 19, 2005
...packs and massage. Certain medications, such as levodopa/carbidopa or tranquilisers such as clonazepam or lorazepam, can be helpful. - Glasgow Sunday Mail,

Valeant's Parkinson's drug still not approved by FDA  Oct 6, 2005
...technology and is being developed as an adjunct treatment in the management of patients with Parkinson's disease being treated with levodopa/carbidopa. - Pharmaceutical Business Review

Options for Parkinson’s Patients Abundant, Says Specialist  Sep 14, 2005
Carbidopa helps reduce adverse effects of levodopa and increases the amount of dopamine in the brain (and not in the rest of the body). ... - SeniorJournal.com,

EFNS: Skin Patch Eases Early and Late Parkinson's Symptoms  Sep 19, 2005
No drug-drug interactions with levodopa, carbidopa, cimetidine or domperidone have been observed, according to Schwarz Pharma AG in Manheim, Germany. - MedPage Today,

5-HTP: Check Before You Swallow  Sep 2, 2005
5-HTP should not be taken with Carbidopa, which is used to treat Parkinsons disease; triptans such as Imitrex, Zomig, Maxalt, or Amerge; and some other ... - headaches.about.com

Solvay Pharmaceuticals launches DUODOPA® - its treatment for  Sep 5, 2005
...and unique treatment based on continuous dopaminergic stimulation by means of a formulation of the well-known substances, levodopa and carbidopa, dispersed in ... - Companynewsgroup (Comunicato Stampa),

Through the Times With Alan F. Schatzberg, MD  Aug 30, 2005
Selegiline is a monoamine oxidase (MAO)-B inhibitor, primarily used orally as an adjunct to L-dopa and carbidopa in the treatment of Parkinson's disease. ... - Psychiatric Times,

Excessive gambling behavior associated with dopamine agonist drugs  Jul 12, 2005
...were taking dopamine agonist medications at levels appropriate for Parkinson's treatment, and eight of the patients also were taking the drug Carbidopa/Levodopa ... - Xagena.it

Parkinson’s Medication Appears to Trigger Excessive Gambling  Jul 11, 2005
...taking dopamine agonist medications at levels appropriate for Parkinson’s treatment, and eight of the patients also were taking the drug carbidopa/levodopa. ... - Newswise (press release)

First-Time Generic Approvals: Rocephin, Sinemet, DDAVP  Jul 8, 2005
...of ceftriaxone sodium 10 g per vial pharmacy bulk packaging for the prevention and treatment of infections caused by susceptible microbes; carbidopa/levodopa 10 ... - Medscape (subscription)

Andreas Heinz, MD , Thomas Siessmeier, MD , Jana Wrase, Dipl. ...  Jul 29, 2005
All subjects were given carbidopa (2.5 mg/kg of body weight) orally 60 minutes before scanning to block extracerebral dopa decarboxylase activity. ... - Am J Psychiatry (subscription)

Parkinson's Treatment Linked to Compulsive Gambling  Jul 11, 2005
In addition, eight of the patients were also taking the medication carbidopa/levodopa, which is a standard therapy for Parkinson's that replenishes dopamine ... - Scientific American

Mylan Reports First Quarter Fiscal 2006 Financial Results  Jul 19, 2005
Increased competition on certain products, primarily omeprazole, carbidopa/levodopa and Amnesteem(TM), was primarily responsible for the price erosion in the ... - Black Enterprise

Medication meant to treat Parkinsons disease has been associated ...  Jul 11, 2005
...able to trace the common link between patients of Parkinson’s disease with the newly acquired habit of gambling to the use of the drug carbidopa/ levodopa. ... - MedIndia <**results**>

First-Time Generic Approvals: Rocephin, Sinemet, DDAVP  Jul 8, 2005
...of ceftriaxone sodium 10 g per vial pharmacy bulk packaging for the prevention and treatment of infections caused by susceptible microbes; carbidopa/levodopa 10 ... - Medscape (subscription)

KV Pharmaceutical Company Reports Fiscal 2005 Results  Jun 14, 2005
...introduced six new products, including four ANDA approvals such as, Morphine Sulfate ER Tabs, 15 and 60 mg, Fluticasone .05% cream and Carbidopa/Levodopa ER ... - Yahoo News (press release)

Neuroleptic Malignant Syndrome in a Patient With Parkinson's ...  Jun 11, 2005
A neurologist reviewed preoperative and postoperative medications and discovered that the carbidopa/ levodopa 25 mg/100 mg dose had been reduced by tab every 3 ... - RedNova.com,

KV Pharmaceutical Company Reports Fiscal 2005 Results  Jun 14, 2005
...introduced six new products, including four ANDA approvals such as, Morphine Sulfate ER Tabs, 15 and 60 mg, Fluticasone .05% cream and Carbidopa/Levodopa ER ... - Yahoo News (press release)

Neuroleptic Malignant Syndrome in a Patient With Parkinson's ...  Jun 11, 2005
A neurologist reviewed preoperative and postoperative medications and discovered that the carbidopa/ levodopa 25 mg/100 mg dose had been reduced by tab every 3 ... - RedNova.com,

CeNeS and Tripos advances COMT research  Apr 13, 2005
Therefore, L-DOPA is formulated with agents that inhibit the breakdown of L-DOPA by DOPA-decarboxylase, such as carbidopa and benserazide. ... - Drug Researcher.com

New PBS drugs to help older Australians  Mar 31, 2005
Stalevo is more convenient for those affected by Parkinson's disease because it is one tablet that combines three drugs - levodopa, carbidopa and entacapone ... - Age (subscription)

CeNeS Pharmaceuticals PLC announces Preliminary Results  Apr 5, 2005
...in Parkinson's disease replacement therapy uses the precursor of dopamine, L-DOPA combined with a dopa-decarboxylase inhibitor (carbidopa or benserazide). ... - Market Wire

COSTA MESA, Californie -- (BUSINESS WIRE) -- March 8, 2005 -  Mar 8, 2005
...several pharmacological agents. The cornerstone of therapy is levodopa (combined with benserazide or carbidopa). However, the long ... - Le Revenu,

Twice As Many Parkinson's Disease Patients Prefer Orally ...  Feb 14, 2005
January 2005 issue of "Clinical Therapeutics" showed that more than twice as many Parkinson's disease patients prefer Parcopa(TM) (carbidopa-levodopa orally ... - PR Newswire (press release)

Valeant Pharmaceuticals Makes a Strong Showing at the Movement ...  Mar 5, 2005
...adverse events reported at a frequency of greater than or equal to 10% when TASMAR was administered in combination with levodopa/carbidopa were dyskinesia ... - Business Wire (press release),

Valeant Pharmaceuticals Launches Tasmar in the European Union  Mar 1, 2005
Tasmar is an adjunctive therapeutic agent used in combination with levodopa and carbidopa for patients with severe Parkinson's disease who are not responding ... - PharmaLive.com (press release),

Restless Legs Syndrome and Periodic Movement in Sleep  Mar 1, 2005
...was improved by pharmacotherapy in 18 of 29 (62%) children (pramipexole [dopamine receptor agonist], oral iron, gabapentin, clonazepam, or carbidopa-L-dopa ... - AAP Grand Rounds (subscription)

Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with levodopa or carbidopa-levodopa combination products.

Symptomatic postural hypotension has occurred when LODOSYN, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. Therefore, when therapy with LODOSYN, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.

For patients receiving monoamine oxidase inhibitors, see CONTRAINDICATIONS. Concomitant therapy with selegiline and carbidopa-levodopa may be associated with severe orthostatic hypotension not attributable to carbidopa-levodopa alone.

There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations.

Dopamine D₂ receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa. In addition, the beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by phenytoin and papaverine. Patients taking these drugs with LODOSYN and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.

Iron salts may reduce the bioavailability of carbidopa and levodopa. The clinical relevance is unclear.

Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.